CNTX
Context Therapeutics Inc.
Set alert
0.19 USD -0.01 -6.25%
0.1888 Day range 0.203
0.1891 52-week range 3.36
- YTD
- -87.14%
- 1 year
- -83.27%
- Open
- 0.203
- Prev close
- 0.2017
- Mkt cap
- 17.37M
- Vol
- 1.01M
- Avg vol
- 1.53M
- EPS
- -0.48
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1888
- High
- 0.203
- Forward P/E
- -3.38
- Beta
- 2.25
- Short ratio
- 2.79
- Inst. own
- 76.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 1.79
- 200-d avg
- 1.86
- 1y target
- 7.70
Key statistics
- Market cap
- 73.50M
- Enterprise value
- 64.96M
- Trailing P/E
- 0.00
- Forward P/E
- -3.38
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.32
- EPS (TTM)
- -0.88
- Beta
- 2.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.33M
- Total cash
- 101.54M
- Total debt
- 0
- Return on equity
- -29.68%
- Shares outstanding
- 75.00M
- Short % of float
- 1.54%
- 50-day average
- 1.79
- 200-day average
- 1.86
Analyst view
Consensus: none
Price target (mean) 7.70 +3971.9% upside
Now 0.1891
- Target (low)
- 4.50
- Target (mean)
- 7.70
- Target (high)
- 10.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy3
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.05.
Financials — quick view
CNTX Revenue — quarterly 0
CNTX Net income — quarterly -14.56M
CNTX EPS — quarterly -0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.11 | -0.22 | -0.11 | -100.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.08 | — | — | — |
| Aug 7, 2024 | Jun 1, 2024 | -0.08 | -0.04 | +0.04 | +50.00% |
| May 8, 2024 | Mar 1, 2024 | -0.38 | -0.23 | +0.15 | +39.47% |
| May 8, 2024 | Mar 1, 2024 | -0.38 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.35 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | D. Boral Capital | init | — | Buy |
| Sep 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | Piper Sandler | init | — | Overweight |
| May 9, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Context Therapeutics Inc.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- contexttherapeutics.com
News
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- New Strong Sell Stocks for October 15th
- New Strong Sell Stocks for October 13th
- Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
- Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move
- Context Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate
- Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Your note
Sign in to keep a note on CNTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LEHR MARTIN A | Chief Executive Officer | Purchase | Feb 20, 2023 | 979,891 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 9.89% | 7,419,355 | 7.27M | Sep 29, 2024 |
| Nextech Invest Ag | 9.89% | 7,419,355 | 7.27M | Sep 29, 2024 |
| Avidity Partners Management, LP | 9.89% | 7,417,155 | 7.27M | Sep 29, 2024 |
| Great Point Partners LLC | 9.25% | 6,934,982 | 6.80M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 7.22% | 5,411,290 | 5.30M | Sep 29, 2024 |
| Vanguard Group Inc | 4.99% | 3,744,961 | 3.67M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4.17% | 3,124,400 | 3.06M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.74% | 554,824 | 543.73K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.39% | 295,078 | 289.18K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 99,061 | 97.08K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 69,665 | 68.27K | Oct 30, 2024 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.07% | 53,125 | 52.06K | Sep 29, 2024 |